Generation of ramoplanin-resistant Staphylococcus aureus

FEMS Microbiology Letters

Volumn 310, Issue 2, 2010, Pages 104-111

  Schmidt, John W ^a   Greenough, Adrienne ^b   Burns, Michelle ^a   Luteran, Andrea E ^a   McCafferty, Dewey G ^a,b  

^a DUKE UNIVERSITY   (United States)

^b Duke University   (United States)

Author keywords

cross resistance; nisin; ramoplanin; Staphylococcus aureus; vancomycin; VISA

Indexed keywords

BACITRACIN; BACTERIAL DNA; CIPROFLOXACIN; CYCLOSERINE; ERYTHROMYCIN; FOSFOMYCIN; GENOMIC DNA; NISIN; OXACILLIN; RAMOPLANIN; RIFAMPICIN; RNA 16S; TRITON X 100; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; BACTERIOLYSIS; BACTERIUM CULTURE; BACTERIUM ISOLATION; CELL SIZE; CONTROLLED STUDY; CROSS RESISTANCE; ELECTRON MICROSCOPY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CELL WALL; DEPSIPEPTIDES; DETERGENTS; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; NISIN; OCTOXYNOL; PHENOTYPE; STAPHYLOCOCCUS AUREUS; TIME FACTORS; VANCOMYCIN;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 77956046791     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1111/j.1574-6968.2010.02051.x     Document Type: Article

References (49)

1. Ayliffe GA (1997) The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 24 (suppl 1) : S74 S79.
2. Bancroft EA (2007) Antimicrobial resistance: it's not just for hospitals. J Am Med Assoc 298 : 1803 1804.
3. Biavasco F, Manso E Varaldo PE (1991) In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob Agents Ch 35 : 195 197.
4. Bonev BB, Breukink E, Swiezewska E, De Kruijff B Watts A (2004) Targeting extracellular pyrophosphates underpins the high selectivity of nisin. FASEB J 18 : 1862 1869.
5. Bozdogan B, Esel D, Whitener C, Browne FA Appelbaum PC (2003) Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemoth 52 : 864 868.
6. Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl H de Kruijff B (1999) Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 286 : 2361 2364.
7. Breukink E, van Heusden HE, Vollmerhaus PJ et al 2003) Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes. J Biol Chem 278 : 19898 19903.
8. Brotz H, Josten M, Wiedemann I, Schneider U, Gotz F, Bierbaum G Sahl HG (1998) Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol Microbiol 30 : 317 327.
9. Chatterjee AN, Wong W, Young FE Gilpin RW (1976) Isolation and characterization of a mutant of Staphylococcus aureus deficient in autolytic activity. J Bacteriol 125 : 961 967.
10. Cudic P, Kranz JK, Behenna DC et al 2002) Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formation. P Natl Acad Sci USA 99 : 7384 7389.
11. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H Hiramatsu K (2000) Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Ch 44 : 2276 2285.
12. Cui L, Ma X, Sato K et al 2003) Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 41 : 5 14.
13. Cui L, Iwamoto A, Lian JQ, Neoh HM, Maruyama T, Horikawa Y Hiramatsu K (2006) Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Ch 50 : 428 438.
14. Cui L, Neoh HM, Shoji M Hiramatsu K (2009) Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Ch 53 : 1231 1234.
15. Fedtke I, Mader D, Kohler T et al 2007) A Staphylococcus aureus ypfP mutant with strongly reduced lipoteichoic acid (LTA) content: LTA governs bacterial surface properties and autolysin activity. Mol Microbiol 65 : 1078 1091.
16. Finegold SM, John SS, Vu AW et al 2004) In vitro activity of ramoplanin and comparator drugs against anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Anaerobe 10 : 205 211.
17. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H Hiramatsu K (1998a) Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemoth 42 : 199 209.
18. Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H Hiramatsu K (1998b) Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J Antimicrob Chemoth 42 : 315 320.
19. Hasper HE, de Kruijff B Breukink E (2004) Assembly and stability of nisin-lipid II pores. Biochemistry 43 : 11567 11575.
20. Howden BP, Johnson PD, Ward PB, Stinear TP Davies JK (2006) Isolates with low-level vancomycin resistance associated with persistent methicillin- resistant Staphylococcus aureus bacteremia. Antimicrob Agents Ch 50 : 3039 3047.
21. Howden BP, Stinear TP, Allen DL, Johnson PD, Ward PB Davies JK (2008) Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob Agents Ch 52 : 3755 3762.
22. Hsu ST, Breukink E, Tischenko E et al 2004) The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat Struct Mol Biol 11 : 963 967.
23. Johnson CC, Taylor S, Pitsakis P, May P Levison ME (1992) Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrob Agents Ch 36 : 2342 2345.
24. Jones RN Barry AL (1989) In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use. Diagn Micr Infec Dis 12 : 279 282.
25. Klevens RM, Morrison MA, Nadle J et al 2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. J Am Med Assoc 298 : 1763 1771.
26. Lu JJ, Lee SY, Hwa SY Yang AH (2005) Septic arthritis caused by vancomycin-intermediate Staphylococcus aureus. J Clin Microbiol 43 : 4156 4158.
27. Mangili A, Bica I, Snydman DR Hamer DH (2005) Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 40 : 1058 1060.
28. Mani N, Tobin P Jayaswal RK (1993) Isolation and characterization of autolysis-defective mutants of Staphylococcus aureus created by Tn917-lacZ mutagenesis. J Bacteriol 175 : 1493 1499.
29. McCafferty DG, Cudic P, Frankel BA et al 2002) Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers 66 : 261 284.
30. Mobarakai N, Quale JM Landman D (1994) Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob Agents Ch 38 : 385 387.
31. Mwangi MM, Wu SW, Zhou Y et al 2007) Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. P Natl Acad Sci USA 104 : 9451 9456.
32. Nam J, Shin D, Rew Y Boger DL (2007) Alanine scan of [l-Dap(2)]ramoplanin A2 aglycon: assessment of the importance of each residue. J Am Chem Soc 129 : 8747 8755.
33. Neoh HM, Cui L, Yuzawa H, Takeuchi F, Matsuo M Hiramatsu K (2008) Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob Agents Ch 52 : 45 53.
34. Neu HC Neu NM (1986) In vitro activity of A-16686, a new glycopeptide. Chemotherapy 32 : 453 457.
35. Novick R (1967) Properties of a cryptic high-frequency transducing phage in Staphylococcus aureus. Virology 33 : 155 166.
36. Opperman TJ, Davey ME, Houseweart C Rogers BL (2003) Ramoplanin is effective against staphylococcal biofilms. Presented at the 43rd ICAAC Abstract no. C1-1119, Chicago, IL. September 14-17, 2003.
37. Pelaez T, Alcala L, Alonso R, Martin-Lopez A, Garcia-Arias V, Marin M Bouza E (2005) In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Ch 49 : 1157 1159.
38. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G Gotz F (1999) Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem 274 : 8405 8410.
39. Pfeltz RF, Singh VK, Schmidt JL et al 2000) Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds. Antimicrob Agents Ch 44 : 294 303.
40. Ristow TA, Noskin GA, Warren JR Peterson LR (1995) In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium. Microb Drug Resist 1 : 335 339.
41. Rolston KV, Dholakia N, Ho DH, LeBlanc B, Dvorak T Streeter H (1996) In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates from cancer patients. J Antimicrob Chemoth 38 : 265 269.
42. Sass P Bierbaum G (2009) Native graS mutation supports the susceptibility of Staphylococcus aureus strain SG511 to antimicrobial peptides. Int J Med Microbiol 299 : 313 322.
43. Sieradzki K Tomasz A (1997) Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 179 : 2557 2566.
44. Sieradzki K Tomasz A (1999) Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J Bacteriol 181 : 7566 7570.
45. Sieradzki K Tomasz A (2003) Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J Bacteriol 185 : 7103 7110.
46. van Heusden HE, de Kruijff B Breukink E (2002) Lipid II induces a transmembrane orientation of the pore-forming peptide lantibiotic nisin. Biochemistry 41 : 12171 12178.
47. Venable JH Coggeshall R (1965) A simplified lead citrate stain for use in electron microscopy. J Cell Biol 25 : 407 408.
48. Walsh TR Howe RA (2002) The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 56 : 657 675.
49. Wiegand I, Hilpert K Hancock RE (2008) Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3 : 163 175.